Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Editorial · Public Accountability

Corrections Log

Public corrections log for US Telehealth Review. How to request a correction, what we log, and our editorial accountability standards.

Published by Ranika Editorial Group LLC Last updated 2026-06-19

How we handle corrections

US Telehealth Review publishes a public corrections log to maintain editorial accuracy and transparency. Every substantive factual correction made to any page on US Telehealth Review is logged here, with the date of correction, the page affected, the nature of the error, and the corrected information.

How to request a correction

Readers, providers, and other parties may request a correction at any time by emailing corrections@ustelehealthreview.com. We respond to every correction request within five business days. Verified corrections are published within 14 days; pricing-driven corrections are typically published within 48 hours.

To expedite review, please include:

  • The page URL where the error appears.
  • The specific sentence or claim that is incorrect.
  • The correct information, with a source we can verify.
  • Your relationship to the subject matter (reader, provider employee, journalist, regulator, etc.).

Corrections log

The corrections log is maintained in reverse chronological order. Each entry includes the date, the page corrected, a description of the prior text, and the corrected text.

2026-06-19 — Site launch

Initial publication of US Telehealth Review with 200+ pages of editorial reviews. The corrections log starts empty and will be updated as substantive factual corrections are made.

What counts as a correction

We log:

  • Factual errors of any size (dates, names, prices, peptide selection, prescriber names, pharmacy partners).
  • Scoring errors that move a provider's total score by one point or more.
  • Misattributed quotes, paraphrases, or statements.
  • Mislabeled images, broken citations, and incorrect external links to authoritative sources.
  • Methodology-rubric application errors.

We do not log (but still fix):

  • Typographical errors that do not change meaning.
  • Pricing updates reflecting a provider's announced change — these are routine updates, not corrections.
  • Editorial style refinements that do not change facts.

Editorial standards

Our full editorial standards, including conflict-of-interest policy, mystery-shopper protocols, and scoring rubric, are published on the methodology page and the editorial standards page.

Membership and accountability

Ranika Editorial Group LLC adheres to the editorial principles of the Society of Professional Journalists Code of Ethics. We are independent of any covered provider and hold no equity in any company covered on US Telehealth Review.

Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
Editor
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing